Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

NCT01089088 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter
Urethral Cancer

Interventions

DRUG: cisplatin
DRUG: gemcitabine hydrochloride
DRUG: sunitinib malate

Sponsor

Cardiff University